Definium Therapeutics (DFTX) Interest Expenses (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Interest Expenses data on file, last reported at $58.2 billion in Q1 2026.

• On a quarterly basis, Interest Expenses rose 9659395.85% year-over-year to $58.2 billion in Q1 2026; TTM through Mar 2026 was $58.2 billion, a 2372407.75% increase from a year earlier, with the FY2025 full-year figure at $30.9 billion, up 645.12% from the prior year.
• Interest Expenses for Q1 2026 stood at $58.2 billion, up from $1.3 million in the prior quarter.
• Over the last five years, Interest Expenses for DFTX reached as high as $58.2 billion in Q1 2026 and fell as low as -$49000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $4.0 billion across 5 years, with a median of $727000.0 in 2024.
• Across the five-year window, Interest Expenses tumbled 100.14% in 2023 and jumped 9659395.85% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $36.1 million in 2022, then slumped by 100.14% to -$49000.0 in 2023, then surged by 1438.78% to $656000.0 in 2024, then soared by 96.04% to $1.3 million in 2025, then soared by 4521685.77% to $58.2 billion in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $58.2 billion in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.